Molecular Profile Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Profile Name KMT2A - MLLT10
Gene Variant Detail

KMT2A - MLLT10 (gain of function)

Relevant Treatment Approaches DOT1L Inhibitor


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KMT2A - MLLT10 leukemia sensitive DOT1L Inhibitor EPZ004777 Preclinical Actionable In a preclinical study, transformed cells expressing the fusion, KMT2A-MLLT10, demonstrated sensitivity to EPZ004777 in culture and in mouse models, resulting in cell cycle arrest, increased apoptotic activity, and inhibition of cell proliferation (PMID: 23138183). 23138183
KMT2A - MLLT10 acute myeloid leukemia sensitive DOT1L Inhibitor I-BET151 + SGC0946 Preclinical - Patient cell culture Actionable In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT10 in culture (PMID: 27294782). 27294782
KMT2A - MLLT10 acute myeloid leukemia predicted - sensitive DSP-5336 Preclinical Actionable In a preclinical study, DSP-5336 treatment led to improved survival in a syngeneic mouse model of acute myeloid leukemia harboring KMT2A-MLLT10 (reported as MLL-AF10) (Blood (2021) 138 (Supplement 1): 3339). detail...